# Questions at the Reference Desk > Research Peptide Fundamentals FAQ — Core Peptides Lab — Research Peptide Fundamentals research peptides FAQ: concise, cited answers about BPC-157, CJC-1295, GHK-Cu, KPV, mechanisms, evidence, safety, and dosing questions. **REFERENCE DESK / FAQ** Direct answers that keep compounds, models, and levels of evidence in their proper places. ## What does BPC-157 do in the body? A complete answer in people is not established. In cells and animal models, BPC-157 is linked to VEGFR2-Akt-eNOS signaling, angiogenesis, cell migration, and tissue-protection pathways [4][7]. Rat studies report gastric-ulcer and transected-tendon healing outcomes [5][6]. Human evidence is limited to a few pilot reports, including a two-adult safety observation that did not test efficacy [1][2]. ## Is BPC-157 a growth hormone? No. BPC-157 is a synthetic fifteen-amino-acid peptide derived from a gastric protein fragment. It is not growth hormone and is not a GHRH analog. Some laboratory work discusses growth-hormone-receptor signaling in tendon cells, but that proposed pathway does not change the compound's identity. CJC-1295 is the member of this set that directly stimulates the growth-hormone axis. ## Does BPC-157 work immediately? Controlled human evidence does not establish that BPC-157 “works” for an injury or condition at any time point. Informal reports sometimes describe early changes, but those reports are anecdotal, not clinical evidence. Animal pharmacokinetic work found rapid elimination and species-dependent exposure [3]; pharmacokinetics alone cannot predict a human treatment effect. ## Does BPC-157 damage the liver? The available evidence cannot define liver risk in a general human population. A pilot involving two healthy adults reported no measurable change in hepatic biomarkers under its study conditions [1]. That sample is far too small to detect uncommon injury or establish long-term safety. Reviews continue to describe the human evidence as extremely limited [2]. ## What is CJC-1295? CJC-1295 is a modified analog of growth-hormone-releasing hormone. Four amino-acid substitutions improve stability, and the DAC form adds an albumin-binding component that extends exposure. Small human studies show prolonged increases in growth hormone and IGF-1 [11][12]. “CJC-1295 no-DAC” is commonly used for Modified GRF 1-29, a shorter-acting form that lacks the albumin-binding component. ## What does CJC-1295 do? It activates GHRH receptors on pituitary somatotroph cells, leading to increased growth-hormone release and downstream IGF-1 production. In small healthy-adult studies, these hormone changes lasted for days and normal pulsatile release remained present [11][12]. Those findings demonstrate target engagement. They do not establish improved recovery, body composition, sleep, performance, or longevity. ## Is CJC-1295 safe? No broad safety conclusion is justified. Human studies are small, early pharmacology experiments, and the compound is not approved for human use. Sustained GH and IGF-1 elevation is measured [11][12], while long-term outcomes are unknown. Fluid retention, glucose regulation, growth signaling, immune responses, and confusion between DAC and no-DAC forms are relevant unresolved cautions. ## How much CJC-1295 should I take? This site does not provide human dosing or medical advice. CJC-1295 has no approved human indication, and informal protocols are not a substitute for controlled evidence. Published experiments used defined compounds under research oversight to study pharmacology [10][11][12]. Their administered amounts should not be converted into personal instructions. ## What does a GHK-Cu peptide do? GHK-Cu binds copper and is studied as a copper carrier and signaling molecule. Cell and review literature links it to fibroblast activity, collagen and elastin matrix regulation, antioxidant pathways, and gene-expression changes [14][16]. Small topical studies provide limited human context, while skin-barrier delivery remains a central formulation challenge [13][17]. ## Is GHK-Cu peptide really anti-aging? “Anti-aging” is broader than the evidence supports. Reviews summarize small topical studies reporting collagen-related and appearance measures [13][16], and a combination hair product showed a signal in forty-five men [15]. These findings do not establish whole-body age reversal, systemic benefit, or long-term disease prevention. The most defensible description is topical skin and matrix research with important delivery limits. ## What is the difference between GHK and GHK-Cu? GHK is the free tripeptide glycyl-histidyl-lysine. GHK-Cu is that peptide bound to a copper(II) ion. Copper coordination contributes to several reported matrix and antioxidant actions, so the forms are not interchangeable. Studies must be read according to which form and formulation were actually tested [13][16][17]. ## What is KPV peptide used for in research? KPV is studied mainly for anti-inflammatory signaling, especially in intestinal cells and mouse colitis. Research links PepT1-mediated uptake to reduced NF-kB and MAP-kinase activation [20]. Mouse studies and targeted delivery systems report improved inflammatory outcomes [18][19][21]. No human clinical trial appears in this corpus, so clinical use and safety are unestablished. --- Core Peptides Lab is an independent reading desk for four distinct peptide research records, with study context in view and no clinical counsel offered.